Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study

BACKGROUND: Treatment options for advanced, well-differentiated neuroendocrine tumours (NETs) remain scarce. Pazopanib is an orally bioavailable, small molecule, multitargeted kinase inhibitor that inhibits VEGF receptors 1, 2, and 3. We did a study of the efficacy of pazopanib with depot octreotide...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lancet Oncol
Hauptverfasser: Phan, Alexandria T, Halperin, Daniel M, Chan, Jennifer A, Fogelman, David R, Hess, Kenneth R, Malinowski, Paige, Regan, Eileen, Ng, Chaan S, Yao, James C, Kulke, Matthew H
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4800487/
https://ncbi.nlm.nih.gov/pubmed/25956795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)70136-1
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge